Browse diseases

…s the evidence is overall low to very low certainty, except for migraine and MTHFR TT homozygosity.…

… median age of 49 years. 50 (90,9%) were diagnosed with chronic migraine and 30 (54,5%) had previously been treated with an anti-CGRP mo…

…ic impact of implementing the protocol.Material and Methods All migraine medication prescriptions between March 2023 and March 2025 were…

…ods Patient and physician data were drawn from the 2022 Adelphi Migraine Disease Specific Programme™. Patients analyzed received rimegep…

… specific triptans (rizatriptan and sumatriptan) and in chronic migraine patients.Conclusions Patients from the rimegepant cohort were m…

…nd, phase 2/3 trial evaluated rimegepant for acute treatment of migraine in participants living in Japan.Methods Participants treated a …

…tments in addition to botulinum toxin has widened the choice of migraine treatment options. However, there is a lack of consistency in t…

…ly resolved. A year later, she had a further milder episode. An epilepsy gene panel identified a likely pathogenic missense variant in t…

…bjectives To evaluate the persistence of anti-CGRP mAbs used in migraine prophylaxis and to identify the main reasons for treatment disc…

… phase 3 trial evaluated rimegepant for preventive treatment of migraine in participants living in Japan.Methods Participants took rimeg…

…on of patients, 69.5%, presented with at least one comorbidity. Hypertension (40.5%) and diabetes mellitus (18.5%) were the most frequent co…

…Traumatic brain injury global prevalence is estimated to be over 55 million, with a di…